1921
Volume 88, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all present drugs have been grandfathered into clinical use, there are no examples of a pre-clinical product evaluation scheme that lead to new candidates for formal development. To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that incorporates and testing of efficacy, toxicity, and pharmacokinetics/metabolism. Particular emphasis is placed on testing, progression from higher-throughput models to those with most clinical relevance, and efficient use of resources.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.11-0812
2013-02-06
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/88/2/216.html?itemId=/content/journals/10.4269/ajtmh.11-0812&mimeType=html&fmt=ahah

References

  1. Desjeux P, , 2001. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95: 239243.[Crossref]
  2. World Health Organization, 2010. Control of the leishmaniases. World Health Organ Tech Rep Ser 949: 1186.
  3. Gonzalez U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J, , 2010. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51: 409419.[Crossref]
  4. Sharlow ER, Grögl M, Johnson J, Lazo JS, , 2010. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease. Mol Interv 10: 7275.[Crossref]
  5. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, , 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a Phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.[Crossref]
  6. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grögl M, Magill AJ, Lazo JS, , 2009. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.[Crossref]
  7. Sharlow ER, Leimgruber S, Yellow-Duke A, Barrett R, Wang QJ, Lazo JS, , 2008. Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. Nat Protoc 3: 13501363.[Crossref]
  8. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH, , 2011. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5: e1253.[Crossref]
  9. Zhu X, Pandharkar T, Werbovetz K, , 2012. Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother 56: 11821189.[Crossref]
  10. Sakthianandeswaren A, Foote SJ, Handman E, , 2009. The role of host genetics in leishmaniasis. Trends Parasitol 25: 383391.[Crossref]
  11. Hanson WL, Chapman WL, Waits VL, Lovelace JK, , 1991. Development of Leishmania (Vianna) panamensis lesions and relationship of numbers of amastigotes to lesion areas on antimony-treated and untreated hamsters. J Parasitol 77: 780783.[Crossref]
  12. Mortelmans K, Zeiger E, , 2000. The Ames Salmonella/M microsome mutagenicity assay. Mutat Res 455: 2960.[Crossref]
  13. Fenech M, , 2000. The in vitro micronucleus technique. Mutat Res 455: 8195.[Crossref]
  14. Sanguinetti M, Mitcheson J, , 2005. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119124.[Crossref]
  15. Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G, , 2009. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53: 51085113.[Crossref]
  16. Silva-Almeida M, Carvalho LO, Abreu-Silva AL, d'Escoffier LN, Calabrese KS, , 2010. Leishmania (Leishmania) amazonensis infection: muscular involvement in BALB/c and C3H.HeN mice. Exp Parasitol 124: 315318.[Crossref]
  17. Castilho TM, Goldsmith-Pestana K, Lozano C, Valderrama L, Saravia NG, McMahon-Pratt D, , 2010. Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease. Eur J Immunol 40: 28162829.[Crossref]
  18. Tonui W, Titus RG, , 2007. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/C mice. Am J Trop Med Hyg 76: 579584.
  19. Morais-Teixeira E, Carvalho AS, Costa J, Duarte SL, Mendonça JS, Boechat N, Rabello A, , 2008. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L. (L.) chagasi and L. (Viannia) braziliensis . Mem Inst Oswaldo Cruz 103: 358362.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.11-0812
Loading
/content/journals/10.4269/ajtmh.11-0812
Loading

Data & Media loading...

  • Received : 30 Dec 2011
  • Accepted : 03 Nov 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error